Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
74 hedge funds and large institutions have $464M invested in Revance Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 12 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.57% less ownership
Funds ownership: 101.04% → 100.46% (-0.57%)
10% less funds holding
Funds holding: 82 → 74 (-8)
11% less capital inflows, than outflows
Capital inflows: $12.8M | Capital outflows: $14.4M
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
91% less call options, than puts
Call options by funds: $16K | Put options by funds: $178K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.22M |
| 2 |
Polar Capital
London,
United Kingdom
|
+$2.2M |
| 3 |
BlackRock Fund Advisors
San Francisco,
California
|
+$1.79M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$1.18M |
| 5 |
PointState Capital
New York
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$2.84M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.77M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$1.36M |
| 4 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$1.28M |
| 5 |
SCM
Suffolk Capital Management
New York
|
-$982K |
RVNC Hedge Fund Activity: Q3 2016 in Review
74 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2016, worth a combined $464M — up 19% from $391M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RVNC and 4 opened new positions — a net loss of 8 holders — while 25 trimmed existing stakes and 30 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $2.22M. The largest seller was Bank of New York Mellon, cutting an estimated $2.84M.
- 74 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2016, down from 82 in Q2 2016.
- Funds reported $464M of Revance Therapeutics, Inc. stock for Q3 2016, up 19% quarter-over-quarter.
- 4 funds opened new Revance Therapeutics, Inc. positions in Q3 2016 and 12 closed out, a net change of -8 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2016 was ArrowMark Colorado Holdings, an estimated $2.22M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2016 was Bank of New York Mellon, an estimated $2.84M sold.
Based on aggregated 13F filings for Q3 2016.